Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that vascular endothelial growth factor-A (VEGF-A)—a potent cytokine—can increase expression of dopamine D2 receptors on endothelial cells.
Scientists at Yale Cancer Center found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
Using single-cell analysis, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found that previously identified subtypes for colorectal cancer may not offer nuanced tumor classification.
Research from Cedars-Sinai Cancer showed that a combination of androgen deprivation therapy plus pelvic lymph node radiation kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, according to a large epidemiologic study led by NCI researchers.
A study led by researchers at the American Cancer Society showed Medicaid expansion under the Affordable Care Act was associated with an increase in two-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people living in rural areas.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult cancer survivors of acute lymphoblastic leukemia and acute myeloid leukemia have reduced long-term survival rates compared to their peers without cancer.
Patients with head and neck cancer undergoing radiation therapy are less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, according to a study led by radiation oncologists at Roswell Park Comprehensive Cancer Center.
“Polypharmacy,” or the concurrent use of multiple medications, can lead to harmful drug interactions—which is especially dangerous for cancer patients about to undergo therapy, according to a study led by Wilmot Cancer Institute researchers.
Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
